|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4439 | |
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2367553 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09771629.4 |
| Europos patento paraiškos padavimo data | 2009-12-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-09-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-05-03 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/066894 |
| Data | 2009-12-04 |
| (87) | Numeris | WO 2010/065939 |
| Data | 2010-06-10 |
| (30) | Numeris | Data | Šalis |
| 120242 P | 2008-12-05 | US |
| (72) |
FARAG, Sherif, S., US
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY |
| COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY |